NewAmsterdam Pharma Company (NAMS) has released an update.
NewAmsterdam Pharma Company N.V. has partnered with several underwriters, including Jefferies LLC and RBC Capital Markets, to launch a public offering of its shares and pre-funded warrants, resulting in an anticipated $188.8 million in net proceeds for the company after expenses. The offering includes over 4 million ordinary shares and warrants, with the underwriters also exercising an option to purchase additional shares. This capital raise, facilitated under a previously effective SEC registration statement, aims to support the company’s growth and development in the pharmaceutical industry.
For further insights into NAMS stock, check out TipRanks’ Stock Analysis page.
